JPSIM Journal of Pakistan Society of Internal Medicine J Pak Soc Intern Med 2709-8729 2710-0804 Pakistan Society of Internal Medicine 10.70302/jpsim.v5i1.2404 jpsim.v5i1.2404 Original Research Frequency of UTI in Diabetic Patients taking SGLT2 Inhibitors Aziz Aisha Kazi Asma docasmakazi@gmail.com * Asim Ammara Javed Rahman Zarar Faisal Saqlain Faaiqa Arif Memorial Teaching Hospital, Rashid Latif Medical College Lahore *Correspondence: Asma Kazi (docasmakazi@gmail.com) 28 02 2024 2024 5 1 375 378 22 09 2023 10 12 2023 Copyright © 2024 The Author(s) 2024 The Author(s) https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective

The objective of this study is to evaluate the frequency of UTI in diabetic patients taking SGLT2 inhibitors.

 Methodology

It was a cross-sectional study in which 125 diabetic patients from Arif Memorial Teaching Hospital, Lahore were enrolled. Data was gathered from individuals with Type 2 diabetes who were undergoing treatment with SGLT2i, either as monotherapy or in combination with other medications, over a span of three months. Data was entered and analyzed through computer software SPSS version 25.0.

 Results

Among 125 diabetic patients, 45.6 were males and 54.4% were females and the mean age was 46.19+8.718 years. Association of UTI with age was found statistically significant while association of UTI with gender, family history of diabetes, duration of diabetes and SGLT2 inhibitors was found statistically insignificant.

 Conclusion

Study concluded that frequency of UTI among diabetic patients taking SGLT2i was 8.8%.

 Keywords : Frequency urinary tract infection diabetes SGLT2 inhibitors References Alsifri S, Almaghamsi AM, Mahfouz AS, Shehab-Eldin W, Rakha S. Safety of empagliflozin in patients with type 2 diabetes mellitus in Saudi Arabia: a post-authorisation safety study. Int J Clin Med. 2023;14(3): 129-47. Alam A, Akbar S, Khan IA, Gul R, Rehman R, Noreen S. Risk factors assessment of type 2 diabetes mellitus in adult male population of Hayatabad, Peshawar: a cross-sectional study. Khyber J Med Sci. 2021; 14(1): 13-7. Azeem S, Khan U, Liaquat A. The increasing rate of diabetes in Pakistan: a silent killer. Ann Med Surg (Lond). 2022; 10.1016/j.amsu.2022. 103901 Azhar M, Hanif M, Rafi S, Ziauddin M, Sohail N, Kumar R. Frequency of urinary tract infections in type 2 diabetes patients taking sodium-glucose cotransporter-2 (SGLT2) inhibitors to regulate their blood sugar level. J Pharm Neg Results. 2023; 14(4): 95-99. Khan S, Hashmi MS, Rana MA, Zafar GM, Asif S, Farooq MT, et al. Frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin. Cureus. 2022; 14(1): e21720. Hussain M, Hussain A, Rehman HU, Iqbal J. Prevalence of genitourinary infections with sodium glucose cotransporter-2 (SGLT2) inhibitors in patients with type 2 diabetes. Pak J Med Health Sci. 2021; 15(10): 2804-7. Ferwani P, Maldar A, Shah N, Chauhan P, Chadha M. Prevalence of bacterial urinary tract infection among patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors: a prospective real-world setting study. J ASEAN Fed Endocr Soc. 2022; 37(2): 5-8. Ashfaq M, Shafique S, Niazi Z, Shah SY, Memon S, Qureshi K, et al. Occurrence of urinary tract infections in type 2 diabetes mellitus patients taking sodium-glucose co-transporter-2 (SGLT-2) inhibitors to regulate their blood sugar levels. Int J Health Sci. 2023; 7(S1): 1947-53. Shrikrishna A, Archana B. Prevalence of genitourinary infection in diabetic patients treated with SGLT 2 inhibitors. Afri Health Sci. 2023; 23(1): 270-5. Bapir R, Bhatti KH, Eliwa A, García-Perdomo HA, Gherabi N, Hennessey D, et al. Risk of urogenital infections in non-diabetic patients treated with sodium glucose transporter 2 (SGLT2) inhibitors. Systematic review and meta-analysis. Arch Italiano Urolog Androlog. 2023; doi: 10.4081/ aiua.2023.11509 Caro MKC, Cunanan EC, Kho SA. Incidence and factors associated with genitourinary infections among Type 2 diabetes patients on SGLT2 Inhibitors: a single retrospective cohort study. Diabetes Epidemiol Manag. 2022; 10.1016/j.deman.2022. 100082 Yang H, Choi E, Park E, Na E, Chung SY, Kim B, et al. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea. Pharmacol Res Perspect. 2022; 10.1002/prp2.910 Liu J, Li L, Li S, Jia P, Deng K, Chen W, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017; 10.1038/s41598-017-02733-w Sarafidis PA, Ortiz A. The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern? Clin Kidney J. 2020; 13(1): 24-6. Figueiredo IR, Rose SCP, Freire NB, Patrocínio MS, Pierdoná N, Bittencourt RJ. Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review. Rev Assoc Med Bras. 2019; 65(2): 246-52. Min SH, Yoon JH, Moon SJ, Hahn S, Cho YM. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Sci Rep. 2018; 8(1): 4466. Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018; 55(5): 503-14. Donnan JR, Grandy CA, Chibrikov E, Marra CA, Aubrey-Bassler K, Johnston K, et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open. 2019; 9(1): e022577. Alkabbani W, Zongo A, Minhas-Sandhu JK, Eurich DT, Shah BR, Alsabbagh MW, et al. Sodium-glucose cotransporter-2 inhibitors and urinary tract infections: a propensity score–matched population-based cohort study. Can J Diabetes. 2022; 46(4): 392-403. Uitrakul S, Aksonnam K, Srivichai P, Wicheannarat S, Incomenoy S. The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: a real-world observational study. Medicines. 2022; 9(12): 59. 10.3390/medicin es9120059